Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present EXACT Sciences Corp. (NASDAQ: EXAS).

Full DD Report for EXAS

You must become a subscriber to view this report.

Recent News from (NASDAQ: EXAS)

EXACT Sciences Is Defying Gravity
Ten days ago, Exact Sciences ( EXAS ) announced that it has signed an agreement with Pfizer ( PFE ) to co-promote Cologuard, EXAS's leading product. EXAS's share price jumped 21% on the news. Immediately following the announcement, analysts published two articles reiterating the news and...
Source: SeekingAlpha
Date: September, 04 2018 13:01
Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Stephen Mandel’s 13F portfolio on a quarterly basis. It is based on Mandel’s regulatory 13F Form filed on 08/14/2018. Please visit our " Tracking Stephen Mandel’s Lone Pine Capital ...
Source: SeekingAlpha
Date: September, 04 2018 06:00
Exact Sciences to participate in September investor conferences
MADISON, Wis. , Aug. 31, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conferences during September and invited investors to participate by webcast. Baird 2018 Global Healthcare Confer...
Source: PR Newswire
Date: August, 31 2018 06:00
Harry Boxer Is Watching 4 Stocks Moving on News & Technical Momentum
I’m watching Exact Sciences Corporation, Ichor Holdings, Ltd., Square and Unisys Corporation today, writes Harry Boxer Wednesday. He's presenting at TradersExpo Las Vegas Nov. 12-14. Exact Sciences Corporation ( EXAS ) popped $2.93 to $75.09 on 3.5 million shares Tuesday. T...
Date: August, 29 2018 07:37
Biotech Analysis Central Pharma News: Shire's Results, Novo Nordisk's Goal, Pfizer And Exact Team Up
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Shire Received FDA Approval For Rare Genetic Disease News: Recently, Shire ( SHPG ) announced that it had received FDA approval for its hereditar...
Source: SeekingAlpha
Date: August, 28 2018 12:37
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
Take Profits On Exact Sciences
Exact Sciences ( EXAS ) recently cut a marketing deal with Pfizer ( PFE ) for Cologuard. That will greatly improve the market penetration of Exact's highly effective and noninvasive colon cancer test. As a result, short sellers have been covering their positions, driving the stock near...
Source: SeekingAlpha
Date: August, 24 2018 17:36
EXACT Sciences Just Amassed The Potential For Incredible Gains
On Wednesday, August 22, 2018, EXACT Sciences ( EXAS ) announced that it has teamed up with Pfizer ( PFE ) surrounding the sale of Cologuard. With Pfizer's strength in the pharmaceutical commercialization space, the news sent the stock climbing. Considering the fact that Cologuard sales are al...
Source: SeekingAlpha
Date: August, 24 2018 09:29
Today's Research Reports on Trending Tickers: Exact Sciences and NovoCure
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. Investors appear to be focused on the upcoming speech from Federal Reserve Chairman Je...
Date: August, 24 2018 08:00
Today's Research Reports on Stocks to Watch: MYnd Analytics and Exact Sciences
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal cancer screening test. Shares of MYnd Analytics also saw big gains with the ...
Date: August, 23 2018 08:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EXAS.

About EXACT Sciences Corp. (NASDAQ: EXAS)

Logo for EXACT Sciences Corp. (NASDAQ: EXAS)

Not available


Contact Information



Current Management

  • John A. McCarthy Jr / CFO

Current Share Structure

  • Market Cap: $6,211,936,349 - 05/16/2018
  • Issue and Outstanding: 121,898,280 - 04/25/2018


Recent Filings from (NASDAQ: EXAS)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 05 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018



Daily Technical Chart for (NASDAQ: EXAS)

Daily Technical Chart for (NASDAQ: EXAS)

Stay tuned for daily updates and more on (NASDAQ: EXAS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EXAS)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EXAS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EXAS and does not buy, sell, or trade any shares of EXAS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: